{"entity":{"id":"checkmate-915","kind":"trial","name":"CheckMate 915","aka":[],"tldr":"CheckMate 915 asked whether adding a low dose of ipilimumab to nivolumab after melanoma surgery would prevent more recurrences; it did not, and added toxicity, so single-agent PD-1 blockade remains the adjuvant standard.","summary":"Nivolumab plus ipilimumab is the most active combination in advanced melanoma, and CheckMate 915 tested whether a lower-toxicity version (ipilimumab 1 mg/kg every six weeks) would improve on nivolumab alone after complete resection of stage IIIB to IV melanoma. It randomised 1844 patients, with recurrence-free survival in the whole population and in PD-L1-low tumours as the dual primary endpoints.\n\nThe combination did not improve recurrence-free survival in either population and caused more treatment-related adverse events. Adjuvant nivolumab or pembrolizumab alone remain the standards, and later trials have tested relatlimab (RELATIVITY-098) and neoadjuvant approaches (NADINA) instead.","status":"negative","asOf":"2026-09-17","links":[{"label":"ClinicalTrials.gov NCT03068455","url":"https://clinicaltrials.gov/study/NCT03068455"}],"tags":["subtype-trials"],"related":[],"cancers":["stage-iii-melanoma","melanoma"],"sections":[],"technologies":[],"targets":[],"drugs":["nivolumab","ipilimumab"],"companies":["bms"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":["jeffrey-weber"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT03068455","phase":"3","setting":"Resected stage IIIB to IV melanoma: adjuvant nivolumab plus low-dose ipilimumab against nivolumab alone","sponsor":"Bristol Myers Squibb","result":"Nivolumab plus low-dose ipilimumab did not improve recurrence-free survival over nivolumab alone after resection of stage III to IV melanoma.","yearReported":2022,"enrolled":1844,"outcomes":[]},"route":"/trials/checkmate-915/","neighbours":{"cancer":[{"id":"melanoma","kind":"cancer","name":"Melanoma","route":"/cancers/melanoma/"},{"id":"stage-iii-melanoma","kind":"cancer","name":"Stage III melanoma (after surgery)","route":"/cancers/stage-iii-melanoma/"}],"drug":[{"id":"ipilimumab","kind":"drug","name":"Ipilimumab","route":"/drugs/ipilimumab/"},{"id":"nivolumab","kind":"drug","name":"Nivolumab","route":"/drugs/nivolumab/"}],"company":[{"id":"bms","kind":"company","name":"Bristol Myers Squibb","route":"/companies/bms/"}],"person":[{"id":"jeffrey-weber","kind":"person","name":"Jeffrey S. Weber","route":"/people/jeffrey-weber/"}]}}